MG
SABS icon

Michael Gelband’s SAB Biotherapeutics SABS Stock Holding History

Michael Gelband’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-768,627
Closed -$2.94M – 1999
2026
Q1 		$2.94M Buy
768,627
+682,514
+793% +$2.72M 0.02% 623
2025
Q4 		$322K Buy
+86,113
New +$283K ﹤0.01% 1293

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Michael Gelband's SABS Position: Q2 2026 in Review

Michael Gelband sold out of SAB Biotherapeutics (SABS) in Q2 2026, closing a stake of 768,627 shares — an estimated $2.94M sold.

Michael Gelband first reported a position in SABS in Q4 2025 and held it in 2 quarters. The position peaked at $2.94M in Q1 2026. 86 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Michael Gelband reported no remaining SAB Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 768,627 SAB Biotherapeutics shares in Q2 2026, an estimated $2.94M.
  • Michael Gelband first reported a position in SAB Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • Michael Gelband's SAB Biotherapeutics position peaked at $2.94M in Q1 2026.
  • 86 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.